<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sumatriptan: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sumatriptan: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sumatriptan: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9968" href="/d/html/9968.html" rel="external">see "Sumatriptan: Drug information"</a> and <a class="drug drug_patient" data-topicid="11064" href="/d/html/11064.html" rel="external">see "Sumatriptan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F224276"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Imitrex;</li>
<li>Imitrex STATdose Refill;</li>
<li>Imitrex STATdose System;</li>
<li>Onzetra Xsail;</li>
<li>Tosymra;</li>
<li>Zembrace SymTouch</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868318"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT SUMAtriptan [DSC];</li>
<li>APO-SUMAtriptan;</li>
<li>DOM-SUMAtriptan [DSC];</li>
<li>Imitrex;</li>
<li>Imitrex DF;</li>
<li>MYLAN-SUMAtriptan;</li>
<li>PMS-SUMAtriptan;</li>
<li>RATIO-SUMAtriptan;</li>
<li>SANDOZ SUMAtriptan [DSC];</li>
<li>SUMAtriptan DF;</li>
<li>TARO-SUMAtriptan;</li>
<li>TEVA-SUMAtriptan;</li>
<li>TEVA-SUMAtriptan DF</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055584"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antimigraine Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812555"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c5d22a7-6932-4862-ad9b-086c6c9df805">Migraine</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine:</b> Limited data available: <b>Note:</b> Results of clinical studies are mixed with regards to efficacy, particularly with oral and SUBQ sumatriptan doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intranasal:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children 5 to 12 years: Intranasal: 5 mg, 10 mg, or 20 mg administered in one nostril <b>as a single dose</b> as soon as possible after the onset of migraine; dose should be selected on an individual basis. A double-blind, placebo-controlled study of 129 patients (mean age: 12.4 years; range: 8 to 17 years) used a weight-based dosing regimen: Body weight: 20 to 39 kg: 10 mg/dose; body weight ≥40 kg: 20 mg/dose; however, relatively few children &lt;12 years of age were included in the study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15037686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15037686'])">Ref</a></span>). A small, randomized, double-blind, placebo-controlled study of 14 children (age range: 6 to 9 years; median: 8.2 years) used intranasal doses of 20 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10227648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10227648'])">Ref</a></span>). A small, retrospective review of 10 children (age range: 5 to 12 years; mean: 9.9 years) used intranasal doses of 5 mg (n=2) or 20 mg (n=8) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11554957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11554957'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Intranasal: 10 mg or 20 mg administered in one nostril <b>as a single dose</b> as soon as possible after the onset of migraine; a lower dose of 5 mg as a single dose may also be effective; dose should be selected on an individual basis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31413171','lexi-content-ref-11192144','lexi-content-ref-31113373','lexi-content-ref-11061765','lexi-content-ref-Winner.2006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31413171','lexi-content-ref-11192144','lexi-content-ref-31113373','lexi-content-ref-11061765','lexi-content-ref-Winner.2006'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> According to the manufacturer, efficacy of oral sumatriptan monotherapy was <b>not</b> established in five controlled trials in adolescent patients; frequency of adverse events was dose-related and age-dependent (ie, younger patients reported more adverse events). Guidelines do not recommend oral sumatriptan alone due to very low confidence in efficacy; however, the combination product of sumatriptan and naproxen is recommended in patients ≥12 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31413171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31413171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: Oral: 25 mg or 50 mg as a single dose administered within 30 minutes of headache onset. There was no statistically significant improvement in pain relief at 2 hours; however, some improvement was noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24163282','lexi-content-ref-9109909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24163282','lexi-content-ref-9109909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>SUBQ:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: SUBQ: 3 to 6 mg as a single dose. An open-label prospective trial of 17 children 6 to 16 years with juvenile migraine used SUBQ doses of 6 mg in 15 patients weighing 30 to 70 kg, and 3 mg/dose in two children weighing 22 kg and 30 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7843952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7843952'])">Ref</a></span>). Another open-label prospective trial in 50 consecutive children (ages 6 to 18 years) with severe migraine used SUBQ doses of 0.06 mg/kg/dose. Relief was reported as good/excellent in 84% of the patients; 16% reported fair to poor relief; additional studies are needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8783473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8783473'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a931b1a-3be3-44de-aef4-42c486dea268">Cyclic vomiting syndrome, abortive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome (CVS), abortive therapy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Based on efficacy data in adolescents and extrapolation from migraine efficacy in children, sumatriptan could be considered for treatment in children &lt;12 years of age with refractory CVS using migraine treatment doses. Dosing for individuals ≥12 years of age is below; for dosing in younger children, refer to <b>Migraine </b>dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31241819','lexi-content-ref-21147834','lexi-content-ref-30076469','lexi-content-ref-10228291','lexi-content-ref-Sunku.2009','lexi-content-ref-35002554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31241819','lexi-content-ref-21147834','lexi-content-ref-30076469','lexi-content-ref-10228291','lexi-content-ref-Sunku.2009','lexi-content-ref-35002554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intranasal:</i> Nasal solution: Children ≥12 years and Adolescents: Intranasal: 20 mg administered as a single dose in 1 nostril; doses should be administered as soon as possible after the onset of prodromal symptoms. If there is no response or partial response to the first dose, may consider repeating after 1 to 2 hours. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31241819','lexi-content-ref-21147834','lexi-content-ref-19794103','lexi-content-ref-30159612','lexi-content-ref-18728540','lexi-content-ref-Sunku.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31241819','lexi-content-ref-21147834','lexi-content-ref-19794103','lexi-content-ref-30159612','lexi-content-ref-18728540','lexi-content-ref-Sunku.2009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>SUBQ:</i> Adolescents: SUBQ: 3 to 6 mg as a single dose; doses should be administered as soon as possible after the onset of prodromal symptoms. If there is no response or partial response to the first dose, some experts recommend repeating after 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8845562','lexi-content-ref-30159612','lexi-content-ref-30076469','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8845562','lexi-content-ref-30159612','lexi-content-ref-30076469','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729838"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment not expected due to extensive metabolism to inactive agents.</p></div>
<div class="block dohp drugH1Div" id="F52729839"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">The following is based on adult data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate hepatic impairment:</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, because the intranasally administered drug does not undergo first-pass metabolism, serum concentrations would not be expected to be altered.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Bioavailability of oral sumatriptan is increased with liver disease. In adults, the maximum dose should not exceed 50 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">SUBQ: No dosage adjustment necessary; has been studied and pharmacokinetics were not altered in patients with hepatic impairment compared to healthy patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Oral, nasal, and SUBQ (Imitrex and Zembrace injection) formulations are contraindicated with severe hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F224280"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9968" href="/d/html/9968.html" rel="external">see "Sumatriptan: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Triptans should <b>not</b> be used within 24 hours of the use of an ergotamine preparation or a different triptan (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7ae4a60-3ca2-4deb-bec1-f4e8197b6a86">Cluster headache, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cluster headache, acute: Note:</b> As monotherapy or in combination with 100% oxygen. Some experts recommend initial treatment with only 100% oxygen if available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-May.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-May.2019'])">Ref</a></span>). Limit use to &lt;10 days per month to avoid medication-overuse headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ </b>(preferred route): Initial: 6 mg once; a lower dose of 3 mg may be effective in select patients (Gregor 2005). If initial dose was effective but headache recurs, may repeat a dose (usually same as first dose) after ≥1 hour; some experts recommend waiting ≥2 hours before repeating a dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-May.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-May.2019'])">Ref</a></span>). Maximum dose: 6 mg per dose; 12 mg in 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal</b> (alternative route) (off-label): Solution: Initial: 20 mg once in single nostril contralateral to side of headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-May.2019','lexi-content-ref-12601104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-May.2019','lexi-content-ref-12601104'])">Ref</a></span>). If initial dose was effective but headache recurs, may repeat the dose after ≥2 hours. Maximum dose: 40 mg in 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When treating acute cluster headache, following initiation of medication(s) for prevention of cluster headaches, patients with ≥2 headaches per day may temporarily receive &gt;2 doses of sumatriptan per day (either SubQ or intranasal at usual dose and interval) until prophylaxis becomes effective, according to some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-May.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-May.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a931b1a-3be3-44de-aef4-42c486dea268">Cyclic vomiting syndrome, abortive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome (migraine associated), abortive therapy (off-label use): Note:</b> To be administered during the prodrome or shortly after vomiting begins (eg, within 30 to 45 minutes); may be used alone for relatively mild or infrequent episodes. If symptoms are frequent or severe, may be used in conjunction with ongoing prophylactic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31241819','lexi-content-ref-Li.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31241819','lexi-content-ref-Li.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal: </b>20 mg; may repeat after 2 hours in patients with no or partial response (maximum: 6 doses/week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Li.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Li.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b>: 6 mg; may repeat after 1 hour in patients with no or partial response (maximum: 6 doses/week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Li.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Li.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment. Some experts recommend a large initial dose, as it may be more effective than multiple smaller doses. When attack is complicated by vomiting or severe nausea, a nonoral preparation may be more effective. Limit use to &lt;10 days per month to avoid medication-overuse headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823','lexi-content-ref-Schwedt.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823','lexi-content-ref-Schwedt.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>50 to 100 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23968886','lexi-content-ref-22336849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23968886','lexi-content-ref-22336849'])">Ref</a></span>). If symptoms persist or return, may repeat dose (usually same as first dose) after ≥2 hours. Maximum dose: 100 mg/dose; 200 mg per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Solution: Usual: 20 mg as a single dose in 1 nostril; if symptoms persist or return, may repeat dose after ≥2 hours. Maximum dose: 40 mg per 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Powder, breath-activated: 22 mg as a single dose; using product-specific device, give as one 11 mg capsule insufflated in each nostril. If symptoms persist or return, may repeat dose after ≥2 hours. Maximum dose: 44 mg per 24 hours. Refer to product-specific administration instructions.</p>
<p style="text-indent:-2em;margin-left:6em;">Spray: 10 mg as a single dose in 1 nostril. If symptoms persist or return, may repeat dose after ≥1 hour. Maximum dose: 30 mg per 24 hours. May also administer at least 1 hour following a dose of another sumatriptan product (use following another 5-HT<sub>1</sub> agonist is contraindicated).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ: </b>Usual: 6 mg once. If symptoms persist or return, may repeat dose (usually same as first dose) after ≥1 hour. If 6 mg was not tolerated, subsequent doses of 1 to 5 mg may provide sufficient relief with better tolerability. Maximum dose: 6 mg/dose; 12 mg per 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990832"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>No data exist regarding the pharmacokinetic disposition of sumatriptan in kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12190330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12190330'])">Ref</a></span>). The following recommendations are extrapolated from pharmacokinetic studies in patients with normal kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, intranasal, SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment [renal clearance accounts for only 20% of total clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12190330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12190330'])">Ref</a></span>)] (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m</b>
<b>
<sup>2</sup></b>
<b>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b></b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988052"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate hepatic impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Bioavailability of oral sumatriptan is increased with liver disease. If treatment is needed, do not exceed single doses of 50 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, dosage adjustment not expected due to extensive non-hepatic metabolism to inactive agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment: Oral, intranasal, and subcutaneous (Imitrex and Zembrace injection) formulations are contraindicated in severe hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F55038176"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac arrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prolonged QT interval on ECG</b> and subsequent ventricular arrhythmias, including <b>torsades de pointes</b> (TdP) and <b>ventricular fibrillation</b> leading to death, have been reported with sumatriptan, most commonly in the presence of additional risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24909575','lexi-content-ref-23216317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24909575','lexi-content-ref-23216317'])">Ref</a></span>). In contrast, postmarketing studies have found no association between triptan use and ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14981171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14981171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurred within 1 hour of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24909575','lexi-content-ref-23216317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24909575','lexi-content-ref-23216317'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QT interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QT prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiac events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coronary artery vasospasm</b>, transient ischemia, <b>acute myocardial infarction</b> (MI), Takotsubo <b>cardiomyopathy</b>, cardiac arrest, and death have been reported with 5-HT<sub>1</sub> agonist administration, including sumatriptan in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20977405','lexi-content-ref-19456882','lexi-content-ref-26587110','lexi-content-ref-11279937','lexi-content-ref-31620447','lexi-content-ref-8682677','lexi-content-ref-23216317','lexi-content-ref-1322217','lexi-content-ref-15319709','lexi-content-ref-17976410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20977405','lexi-content-ref-19456882','lexi-content-ref-26587110','lexi-content-ref-11279937','lexi-content-ref-31620447','lexi-content-ref-8682677','lexi-content-ref-23216317','lexi-content-ref-1322217','lexi-content-ref-15319709','lexi-content-ref-17976410'])">Ref</a></span>). <b>Increased blood pressure</b>, including <b>hypertensive crisis</b>, has been reported on rare occasions in patients with and without a history of hypertension. In contrast, postmarketing studies have found no association between triptan use and MI or non-MI ischemic heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14981171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14981171'])">Ref</a></span>). The American Headache Society's consensus statement on the cardiovascular safety profile of triptans noted the safety of this drug class in patients with migraines without known or clinically suspected coronary artery disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15147249','lexi-content-ref-15149490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15147249','lexi-content-ref-15149490'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, vasoconstriction). Binds to 5-HT<sub>1B</sub> receptors in coronary arteries and has been shown to narrow human coronary arteries in vivo by 10% to 20% during angiography (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12904112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12904112'])">Ref</a></span>). At therapeutic doses, triptans, which are 5-HT<sub>1B</sub>/<sub>1D</sub> agonists, have minimal potential to cause significant constriction of nondiseased arteries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15149489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15149489'])">Ref</a></span>). For chest symptoms, nonischemic mechanisms are hypothesized, including direct effect on the pulmonary vasculature, alterations in skeletal muscle energy metabolism and heightened sensory sensitivity during a migraine attack (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15147249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15147249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; symptoms of acute myocardial infarction developed between 10 to 180 minutes (median 15 minutes) in patients taking sumatriptan subcutaneously and from 30 to 60 minutes (median 60 minutes) following oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20977405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20977405'])">Ref</a></span>). Onset of chest symptoms was generally 5 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8980858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8980858'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for coronary artery disease (CAD) (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20977405','lexi-content-ref-19456882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20977405','lexi-content-ref-19456882'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cerebrovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemorrhagic stroke </b>(including<b> subarachnoid hemorrhage</b>) and <b>ischemic stroke</b> have been reported in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7909130','lexi-content-ref-11342701','lexi-content-ref-Coulter.2002','lexi-content-ref-21681368','lexi-content-ref-7560482','lexi-content-ref-16472339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7909130','lexi-content-ref-11342701','lexi-content-ref-Coulter.2002','lexi-content-ref-21681368','lexi-content-ref-7560482','lexi-content-ref-16472339'])">Ref</a></span>). A study of FDA adverse event reports indicated that there may be a significant, although rare, risk of severe ischemic cerebrovascular events in patients on triptans (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23921799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23921799'])">Ref</a></span>). In contrast, several cohort studies have not found an association between triptan use and stroke or transient ischemic attacks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14981171','lexi-content-ref-15209685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14981171','lexi-content-ref-15209685'])">Ref</a></span>). Since migraine is an independent risk factor for stroke (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27211561','lexi-content-ref-27283278','lexi-content-ref-24085027','lexi-content-ref-20493462','lexi-content-ref-16097850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27211561','lexi-content-ref-27283278','lexi-content-ref-24085027','lexi-content-ref-20493462','lexi-content-ref-16097850'])">Ref</a></span>), it is challenging to define the role of triptans in precipitating stroke.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, vasoconstriction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7909130','lexi-content-ref-11167896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7909130','lexi-content-ref-11167896'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; generally occurs within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11342701','lexi-content-ref-7560482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11342701','lexi-content-ref-7560482'])">Ref</a></span>) and may present as quickly as 4 minutes after SubQ injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7909130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7909130'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Migraine (independent risk factor for stroke) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29593023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29593023'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31566723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31566723'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of estrogen-based oral contraceptives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31566723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31566723'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Young females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31566723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31566723'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS depression, such as <b>dizziness</b>, <b>asthenia</b>, or <b>drowsiness</b>, which may impair physical or mental abilities, have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12383060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12383060'])">Ref</a></span>). Other CNS effects, including abnormal dreams, agitation, ataxia, confusion, <b>tremor,</b> and <b>vertigo</b>, may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12383060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12383060'])">Ref</a></span>). Analysis of double-blind, placebo-controlled trials suggest that CNS adverse reactions, such as drowsiness and asthenia, may be related to unmasking of CNS symptoms associated with resolution of the migraine attack rather than representing drug-related adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17381558']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17381558'])">Ref</a></span>). There are also reports of <b>akathisia</b>, acute <b>dystonia</b>, and pathological laughter associated with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17868284','lexi-content-ref-7841582','lexi-content-ref-9120496','lexi-content-ref-9731945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17868284','lexi-content-ref-7841582','lexi-content-ref-9120496','lexi-content-ref-9731945'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to pharmacologic action. Despite the hydrophilicity of sumatriptan, it has been shown to cross the blood-brain barrier and penetrate the CNS causing pharmacological effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20012125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20012125'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; akathisia has been reported to occur within 5 to 10 minutes of SubQ administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9120496']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9120496'])">Ref</a></span>). Dystonia has been reported to occur within 15 to 60 minutes of oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9120496','lexi-content-ref-9731945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9120496','lexi-content-ref-9731945'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15154851','lexi-content-ref-12383060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15154851','lexi-content-ref-12383060'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lipophilicity (almotriptan 12.5 mg, naratriptan 2.5 mg, and sumatriptan 50 mg with the lowest incidence and eletriptan 40 and 80 mg, rizatriptan 10 mg, and zolmitriptan 2.5 and 5 mg with the highest incidence) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15154851','lexi-content-ref-15663606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15154851','lexi-content-ref-15663606'])">Ref</a></span>); however, other studies have not shown a correlation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10940090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10940090'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Transient and permanent <b>blindness</b> and significant partial <b>vision loss</b> have been reported with use in adult and pediatric patients. Since visual disorders may be part of a migraine attack, a causal relationship between these events and the use of 5-HT<sub>1</sub> agonists has not been clearly established. Other ocular effects include accommodation disorders, conjunctivitis, disorders of sclera, external ocular muscle disorders, eye edema and swelling, eye hemorrhage, eye itching, eye pain, keratitis, mydriasis, and visual disturbances. Other reported ocular effects include ischemic <b>optic neuropathy</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8014044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8014044'])">Ref</a></span>), <b>oculomotor nerve paralysis</b> resulting in double vision and ptosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27858938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27858938'])">Ref</a></span>), recurrent paresis of the superior division of the oculomotor nerve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Saadati.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Saadati.2001'])">Ref</a></span>), and bilateral <b>angle-closure glaucoma</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28562545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28562545'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; ischemic ocular effects may be related to the pharmacologic action (ie, vasoconstriction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27858938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27858938'])">Ref</a></span>). Acute intraocular pressure elevation: Unknown; however, serotonin may play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28562545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28562545'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Bilateral angle-closure glaucoma: Rapid; occurred within 1 week of 1 dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28562545']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28562545'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other vasospasm-related events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral</b>
<b>ischemia</b>, <b>reversible cerebral vasoconstriction syndrome</b> (RCVS), <b>ischemic colitis</b>, <b>splenic infarction</b>, and <b>Raynaud's disease</b> have been reported with 5-HT<sub>1</sub> agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16767537','lexi-content-ref-15596760','lexi-content-ref-20051552','lexi-content-ref-27904122','lexi-content-ref-24442762','lexi-content-ref-30169369']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16767537','lexi-content-ref-15596760','lexi-content-ref-20051552','lexi-content-ref-27904122','lexi-content-ref-24442762','lexi-content-ref-30169369'])">Ref</a></span>). In a review of drug-induced Raynaud syndrome, triptans were not identified as a cause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26949933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26949933'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: RCVS: Unknown; may be caused by transient dysregulation of cerebral vascular autonomic regulation mechanism resulting in multifocal vasoconstriction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169369']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169369'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median onset of 2 days in case reports of ischemic colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20051552','lexi-content-ref-9759693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20051552','lexi-content-ref-9759693'])">Ref</a></span>) to onset of 6 months in a case report of cerebral vasospasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15596760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15596760'])">Ref</a></span>). In one review, serious vascular adverse events occurred after the first administration in 5 patients, after 2 to 4 administrations in 5 patients and after months or years in 15 patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19456882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19456882'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of drugs, such as dihydroergotamine, methysergide, and selective serotonin reuptake inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19456882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19456882'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonin syndrome may occur, particularly when used concomitantly with other serotonergic drugs. Serotonin syndrome occurs primarily through activation of 5-HT<sub>2A</sub> receptors, although 5-HT<sub>1A</sub> receptors may also play a role. Triptans are serotonin agonists with weak affinity for the 5-HT<sub>1A</sub> subtype and no activity at 5-HT<sub>2</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19925619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19925619'])">Ref</a></span>). Since triptans have no activity at the 5-HT<sub>2</sub> receptors, they theoretically should not cause serotonin syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22221260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22221260'])">Ref</a></span>); however, animal models have suggested that repeated exposure to triptans, including overdose, may induce serotonin syndrome via upregulation of serotonin synthesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22755550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22755550'])">Ref</a></span>). Onset typically occurs minutes to hours after initiation, dose increase, or addition of a serotonergic drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30315014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30315014'])">Ref</a></span>). Risk factors may include concomitant use of other serotonergic drugs, including selective serotonin reuptake inhibitors or selective norepinephrine reuptake inhibitors antidepressants; however, literature is conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18092054','lexi-content-ref-20618823','lexi-content-ref-FDA.2006','lexi-content-ref-9475817','lexi-content-ref-10524661','lexi-content-ref-22289074','lexi-content-ref-18480219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18092054','lexi-content-ref-20618823','lexi-content-ref-FDA.2006','lexi-content-ref-9475817','lexi-content-ref-10524661','lexi-content-ref-22289074','lexi-content-ref-18480219'])">Ref</a></span>). Concomitant use of opioids may also increase risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2016'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F224245"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (30% to 59%; including bleeding at injection site, bruising at injection site, burning sensation at injection site, erythema at injection site, pain at injection site, swelling at injection site, warm sensation at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤12%)<span class="lexi-table-link-container"> (<a aria-label="DizzinessInjection table link" class="lexi-table-link" data-table-id="lexi-content-dizzinessinjection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizzinessinjection')">table 1</a>)</span><span class="table-link" style="display:none;">DizzinessInjection</span>, feeling hot (≤11%), tingling sensation (14%), vertigo (≤12%)<span class="lexi-table-link-container"> (<a aria-label="VertigoInjection table link" class="lexi-table-link" data-table-id="lexi-content-vertigoinjection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vertigoinjection')">table 2</a>)</span><span class="table-link" style="display:none;">VertigoInjection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="DizzinessInjection" frame="border" id="lexi-content-dizzinessinjection" rules="all">
<caption style="text-align:center;">
<b>Sumatriptan: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">547</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="VertigoInjection" frame="border" id="lexi-content-vertigoinjection" rules="all">
<caption style="text-align:center;">
<b>Sumatriptan: Adverse Reaction: Vertigo</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">547</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (5%), chest pressure (2%), chest tightness (3%), flushing (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local discomfort (jaw or throat: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (5%)<span class="lexi-table-link-container"> (<a aria-label="AstheniaInjection table link" class="lexi-table-link" data-table-id="lexi-content-astheniainjection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-astheniainjection')">table 3</a>)</span><span class="table-link" style="display:none;">AstheniaInjection</span>, burning sensation (7%), drowsiness (≤3%)<span class="lexi-table-link-container"> (<a aria-label="DrowsinessInjection table link" class="lexi-table-link" data-table-id="lexi-content-drowsinessinjection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsinessinjection')">table 4</a>)</span><span class="table-link" style="display:none;">DrowsinessInjection</span>, feeling of heaviness (7%), headache (2%), numbness (5%), paresthesia (5%), sedated state (≤3%), sensation of pressure (7%), sensation of tightness (5%), strange feeling (2%), tight feeling in the head (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="AstheniaInjection" frame="border" id="lexi-content-astheniainjection" rules="all">
<caption style="text-align:center;">
<b>Sumatriptan: Adverse Reaction: Asthenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">547</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="DrowsinessInjection" frame="border" id="lexi-content-drowsinessinjection" rules="all">
<caption style="text-align:center;">
<b>Sumatriptan: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">547</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as drowsiness/sedation</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (2%), neck pain (≤5%), neck stiffness (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (1%), nasal discomfort (nasal cavity: ≤2%), sinus discomfort (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Nasal:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (≤25%), nausea (≤14%), vomiting (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Unusual taste (≤25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal discomfort (≤11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local irritation (≤5%), localized burning (1%), localized numbness (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤2%)<span class="lexi-table-link-container"> (<a aria-label="DizzinessNasal table link" class="lexi-table-link" data-table-id="lexi-content-dizzinessnasal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizzinessnasal')">table 5</a>)</span><span class="table-link" style="display:none;">DizzinessNasal</span>, paresthesia (≤5%), vertigo (≤2%)<span class="lexi-table-link-container"> (<a aria-label="VertigoNasal table link" class="lexi-table-link" data-table-id="lexi-content-vertigonasal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vertigonasal')">table 6</a>)</span><span class="table-link" style="display:none;">VertigoNasal</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="DizzinessNasal" frame="border" id="lexi-content-dizzinessnasal" rules="all">
<caption style="text-align:center;">
<b>Sumatriptan: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nasal spray</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,007</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">704</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nasal spray</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">704</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nasal spray</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,212</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">704</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="VertigoNasal" frame="border" id="lexi-content-vertigonasal" rules="all">
<caption style="text-align:center;">
<b>Sumatriptan: Adverse Reaction: Vertigo</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nasal spray</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,007</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">704</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nasal spray</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">496</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">704</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nasal spray</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,212</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">704</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Defined as dizziness/vertigo</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal cavity pain (≤5%), rhinitis (2%), rhinorrhea (≤5%), sinus discomfort (≤4%), sore nose (≤5%)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Tablet:</b></p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (≤2%), chest pressure (≤2%), chest tightness (≤2%), hot and cold flashes (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Sore throat (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (≤3%), feeling of heaviness (≤3%), heaviness of chest (≤2%), malaise (≤3%), pain (≤8%), paresthesia (3% to 5%), sensation of pressure (≤8%), sensation of tightness (≤3%), vertigo (2%)<span class="lexi-table-link-container"> (<a aria-label="VertigoTablet table link" class="lexi-table-link" data-table-id="lexi-content-vertigotablet" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vertigotablet')">table 7</a>)</span><span class="table-link" style="display:none;">VertigoTablet</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="VertigoTablet" frame="border" id="lexi-content-vertigotablet" rules="all">
<caption style="text-align:center;">
<b>Sumatriptan: Adverse Reaction: Vertigo</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (</b>
<b>Sumatriptan</b>
<b>)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">437</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">309</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">771</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">309</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">417</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">309</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Jaw pain (≤3%), jaw pressure (≤3%), jaw tightness (≤3%), neck pain (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngeal edema (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Postmarketing (any route):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Chalaupka 2009), cardiomyopathy (takotsubo) (Mohan 2019), coronary artery vasospasm (Stricker 1992), hypertensive crisis, increased blood pressure, myocarditis (eosinophilic) (Al Ali 2006), palpitations, peripheral ischemia, prolonged QT interval on ECG (Stillman 2013), Raynaud disease, torsades de pointes (Stillman 2013), ventricular fibrillation (Laine 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (Pradalier 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ischemic colitis (Nguyen 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Splenic infarction (Arora 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Lee 2020), angioedema (Dachs 1995), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia (López-Alemany 1997), cerebellar infarction (Jayamaha 1995), dystonia (Singhal 2002), heaviness in neck (includes jaw or throat), hemorrhagic stroke (Combremont 2001), ischemic stroke (Gazioglu 2012), reversible cerebral vasoconstriction syndrome (Kato 2016), seizure (Kumlien 2010), subarachnoid hemorrhage (Pfadenhauer 2006), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Neck pressure, neck tightness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Angle-closure glaucoma (Hsu 2017), blindness, oculomotor nerve paralysis (Novistkaya 2017), optic neuropathy (Chiari 1994), vision loss (partial) (Novistkaya 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p></div>
<div class="block coi drugH1Div" id="F224259"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, angioedema, anaphylaxis) to sumatriptan or any component of the formulation; ischemic heart disease or signs or symptoms of ischemic heart disease (coronary artery vasospasm, Prinzmetal angina, angina pectoris, MI, silent myocardial ischemia); history of cerebrovascular syndromes (including strokes, transient ischemic attacks), history of hemiplegic or basilar migraine; peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT<sub>1</sub> agonist; concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Valvular heart disease; significant underlying cardiovascular disease (eg, atherosclerotic disease, congenital heart disease); ophthalmoplegic migraine.</p></div>
<div class="block war drugH1Div" id="F224242"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use oral formulations of sumatriptan with caution (and with dosage limitations) in patients with mild to moderate hepatic impairment where treatment is necessary and advisable. Presystemic clearance of orally administered sumatriptan is reduced in hepatic impairment, leading to increased plasma concentrations; dosage reduction of the oral product is recommended. Non-oral routes of administration (intranasal, subcutaneous) do not undergo similar hepatic first-pass metabolism and are not expected to result in significantly altered pharmacokinetics in patients with hepatic impairment. Use of the oral, intranasal, Imitrex, and Zembrace injectable is contraindicated in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with history of seizure disorder or in patients with a lowered seizure threshold; seizures have been reported after sumatriptan administration in patients with or without a history of seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; perform a cardiovascular evaluation prior to initiation of therapy in older adult patients with cardiovascular risk factors (eg, diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease) and periodically during intermittent long-term use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The packaging (needle cover of prefilled syringe) may contain dry natural rubber, which is a derivative of latex.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Only indicated for the acute treatment of migraine or cluster headache (depending on product); not indicated for migraine or cluster headache prophylaxis, or for the treatment of hemiplegic or basilar migraine. Acute migraine agents (eg, 5-HT<sub>1</sub> agonists, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse. If a patient does not respond to the first dose, the diagnosis of migraine or cluster headache should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine or cluster headache.</p></div>
<div class="block foc drugH1Div" id="F224252"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Exhaler Powder, Nasal, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Onzetra Xsail: 11 mg per nosepiece (2 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex: 5 mg/actuation (1 ea [DSC]); 20 mg/actuation (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tosymra: 10 mg/actuation (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex: 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zembrace SymTouch: 3 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex STATdose System: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zembrace SymTouch: 3 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex STATdose Refill: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/0.5 mL (0.5 mL [DSC]); 6 mg/0.5 mL (0.5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/0.5 mL (0.5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex: 25 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F224238"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F224261"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Exhaler Powder</b> (Onzetra Xsail Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11MG/NOSEPC (per each): $70.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (SUMAtriptan Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/ACT (per each): $59.04 - $81.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/ACT (per each): $42.80 - $81.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (SUMAtriptan Succinate Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/0.5 mL (per 0.5 mL): $13.20 - $85.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tosymra Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/ACT (per each): $117.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Imitrex STATdose System Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/0.5 mL (per 0.5 mL): $289.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/0.5 mL (per 0.5 mL): $289.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (SUMAtriptan Succinate Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/0.5 mL (per 0.5 mL): $107.36 - $187.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/0.5 mL (per 0.5 mL): $92.20 - $112.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Zembrace SymTouch Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg/0.5 mL (per 0.5 mL): $207.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Imitrex STATdose Refill Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/0.5 mL (per 0.5 mL): $274.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/0.5 mL (per 0.5 mL): $274.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Imitrex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $41.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $90.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $90.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (SUMAtriptan Succinate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $23.72 - $28.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $25.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $25.14</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868319"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex: 6 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imitrex DF: 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block exp drugH1Div" id="F11450256"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 5 mg/mL oral liquid preparation made from tablets and one of three different vehicles (Ora-Sweet®, Ora-Sweet® SF, or Syrpalta® syrups). <b>Note:</b> Ora-Plus® Suspending Vehicle is used with Ora-Sweet® or Ora-Sweet® SF to facilitate dispersion of the tablets (Ora-Plus® is not necessary if Syrpalta® is the vehicle). Crush nine 100 mg tablets in a mortar and reduce to a fine powder. Add 40 mL of Ora-Plus® in 5 mL increments and mix thoroughly between each addition; rinse mortar and pestle 5 times with 10 mL of Ora-Plus®, pouring into bottle each time, and add quantity of appropriate syrup (Ora-Sweet® or Ora-Sweet® SF) sufficient to make 180 mL. Store in amber glass bottles in the dark; label "shake well", "refrigerate", and "protect from light". Stable for 21 days refrigerated.</p>
<div class="reference">Fish DN, Beall HD, Goodwin SD, et al, "Stability of Sumatriptan Succinate in Extemporaneously Prepared Oral Liquids," <i>Am J Health Syst Pharm</i>, 1997, 54(14):1619-22.<span class="pubmed-id">9248606</span></div>
</div>
<div class="block admp drugH1Div" id="F52613893"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Administer as soon as symptoms appear.</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Each nasal spray unit is preloaded with 1 dose; <b>do not</b> test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert nozzle into nostril about <sup>1</sup>/<sub>2</sub> inch; close mouth; take a breath through nose while releasing spray into nostril by pressing firmly on blue plunger; remove nozzle from nostril; keep head level for 10 to 20 seconds and gently breathe in through nose and out through mouth; <b>do not breathe deeply</b>.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with water or other fluids; swallow tablet whole; do not split tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: Administer SUBQ only; do <b>not</b> administer IM; do <b>not</b> administer IV (may cause coronary vasospasm). Needle penetrates <sup>1</sup>/<sub>4</sub> inch of skin; use in areas of the body with adequate skin and SUBQ thickness (lateral thigh or upper arm). Do not use the auto-injector device for doses that are not 4 to 6 mg; vials should be used.</p></div>
<div class="block adm drugH1Div" id="F224256"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer as soon as symptoms appear.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Powder: For intranasal administration with the Xsail device only. Remove the clear device cap from the reusable delivery device; remove one 11 mg disposable nosepiece from the foil pouch and click into the device body. Prior to administration, pierce the capsule inside the nosepiece by pressing and releasing the white piercing button one time on the device body. Insert the nosepiece into one nostril so there is a tight seal; rotate the device to place the mouthpiece in the mouth. Blowing forcefully through the mouthpiece for 2 to 3 seconds will deliver the powder into the nasal cavity; vibration may occur. Do not press white button while blowing into mouthpiece. Once administered into the first nostril, remove and discard nosepiece; repeat same process using a second 11 mg nosepiece into the other nostril to administer the remainder of the 22 mg dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Each nasal spray unit is preloaded with 1 dose; <b>do not </b>test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert nozzle into nostril about <sup>1</sup>/<sub>2</sub> inch; close mouth; take a breath through nose while releasing spray into nostril by pressing firmly on blue plunger; remove nozzle from nostril; keep head level for 10 to 20 seconds and gently breathe in through nose and out through mouth; <b>do not breathe deeply</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Spray: Each nasal spray unit is preloaded with 1 dose; <b>do not </b>test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert half of the spray nozzle into nostril and angle outward; tilt head back slightly and breath slowly through nose while releasing spray into nostril by pressing firmly on plunger; remove nozzle from nostril; keep head level for 10 to 20 seconds and gently breathe in through nose and out through mouth; <b>do not breathe deeply</b>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Not for IM or IV use. Needle penetrates <sup>1</sup>/<sub>4</sub> inch of skin; use in areas of the body with adequate skin and subcutaneous thickness (lateral thigh or upper arm). In patients receiving doses other than 4 or 6 mg, use the 6 mg single-dose vial instead of the autoinjector device.</p></div>
<div class="block sts drugH1Div" id="F224273"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injectable:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Imitrex: Store at 2°C to 30°C (36°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:4em;">Zembrace: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Powder: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F); do not refrigerate or freeze. Use nosepiece immediately after removing from pouch.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F); do not refrigerate or freeze.</p>
<p style="text-indent:-2em;margin-left:4em;">Spray: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F); do not refrigerate or freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Tablet: Store at 2°C to 30°C (36°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53568985"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Injection, intranasal, and tablets: Acute treatment of migraine with or without aura (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Injection (excluding Zembrace): Acute treatment of cluster headaches (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used intranasally and subcutaneously as abortive therapy for cyclic vomiting syndrome.</p></div>
<div class="block mst drugH1Div" id="F224330"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">SUMAtriptan may be confused with SAXagliptin, SITagliptin, somatropin, ZOLMitriptan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300101"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F224247"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the adverse/toxic effect of Serotonin 5-HT1D Receptor Agonists (Triptans). Management: Consider alternatives to this combination when possible. If combined, monitor for increased bromocriptine and triptan toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Monoamine Oxidase Inhibitors may increase the serum concentration of Serotonin 5-HT1D Receptor Agonists (Triptans). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of other Serotonin 5-HT1D Receptor Agonists (Triptans).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F224262"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In a study using full-term, healthy human placentas, limited amounts of sumatriptan were found to cross the placenta (Schenker 1995).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnancy outcome data for sumatriptan are available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 617 pregnancies (626 infants/fetuses; 528 with first trimester exposure) exposed to sumatriptan (including 7 pregnancies also exposed to naratriptan). Following sumatriptan exposure, the risk of major birth defects following first trimester exposure was 4.2% and no consistent pattern of birth defects was observed. The pregnancy registry was closed to enrollment in January 2012 (Ephross 2014). Data from the pregnancy registry were compared to data obtained from an insurance claims database. Between 1996 and 2012, the database recorded 3,496 pregnancies with first trimester exposure to sumatriptan. The risk of major birth defects was the same as that observed in the pregnancy registry (4%) (Yusuf 2018).</p>
<p style="text-indent:0em;margin-top:2em;">An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist (triptan) exposure. An increased risk of major congenital malformations was not observed following sumatriptan exposure (2,229 exposed during the first trimester) (Källén 2011). An increased risk of major congenital malformations was also not observed using data collected from a Norwegian pregnancy registry study. This study included 415 women who used sumatriptan during the first trimester of pregnancy between 2004 and 2007 (Nezvalová-Henriksen 2013). A meta-analysis of six studies, most evaluating sumatriptan (including Källén 2011 and Nezvalová-Henriksen 2013), did not find triptan exposure in pregnancy to increase the risk for major congenital malformations, low birth weight, or birth &lt;37 weeks' gestation (Dudman 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Triptans relieve migraine pain by selectively binding to serotonin receptors, resulting in vasoconstriction of cranial arteries. Although the effects on uterine blood flow have not been evaluated, 1 case report suggests excessive use of a triptan may cause placental hypoperfusion (ACOG 2022; Viard 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). Triptans are not the preferred initial treatment for acute migraine headache in pregnant patients (ACOG 2022). If a triptan is needed when first-line therapy is ineffective, sumatriptan may be considered under close supervision. Triptans should be avoided in pregnant patients with cardiac disease or hypertension (ACOG 2022; CHS [Worthington 2013]; EHF [Steiner 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Acute treatment of cluster headache in pregnant patients is similar to nonpregnant adults; however, if effective, use of sumatriptan nasal spray may be preferred over SUBQ to limit systemic exposure (AHS [Robbins 2016]; Bjørk 2021; Schindler 2022).</p></div>
<div class="block mopp drugH1Div" id="F53795304"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Headache severity, blood pressure, signs/symptoms suggestive of angina; perform a cardiovascular evaluation prior to initiation of therapy in 5-HT<sub>1</sub> agonist-naive patients who have multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease); monitor ECG with first dose in patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation and consider periodic cardiovascular evaluation in such patients during intermittent long-term use.</p></div>
<div class="block pha drugH1Div" id="F224241"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective agonist for serotonin (5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors) on intracranial blood vessels and sensory nerves of the trigeminal system; causes vasoconstriction and reduces neurogenic inflammation associated with antidromic neuronal transmission correlating with relief of migraine</p></div>
<div class="block phk drugH1Div" id="F224258"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: ~30 minutes; Intranasal: ~15 to 30 minutes; SUBQ: ~10 minutes; Peak effect: Oral: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub> (central): SUBQ: 50 L; V<sub>d</sub> (apparent): Oral, Intranasal: 2.7 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 14% to 21%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to an indole acetic acid metabolite (inactive) which then undergoes ester glucuronide conjugation; may be metabolized by monoamine oxidase (MAO); extensive first-pass metabolism following oral administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Intranasal: Solution 17% (compared to SUBQ), Powder 19% (compared to SUBQ), Spray 58% to 87% (compared to SUBQ); Oral: 15%; SUBQ: 97% ± 16%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Distribution: 15 minutes; Terminal: 2 hours; range: 1 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 2 to 2.5 hours; Intranasal: Powder: ~45 minutes; Spray: Median 10 minutes (range: 5 to 23 minutes); SUBQ: 12 minutes (range: 4 to 20 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Urine (42% of total dose as indole acetic acid metabolite; 3% of total dose as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Urine (~60% of total dose, mostly as indole acetic acid metabolite; 3% of total dose as unchanged drug); feces (~40%).</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Urine (38% of total dose as indole acetic acid metabolite; 22% of total dose as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51221474"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Bioavailability following oral administration may be markedly increased in patients with hepatic disease.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F224264"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumafix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Micralgin | Micranil | Migraneitor | Migratriptan | Sumatriptan servycal | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptan 1a pharma | Sumatriptan actavis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo sumatriptan | Chemmart Sumatriptan | Clustran | Imigran | Imigran Mk II | Iptam | Sumatab | Sumatran | Sumatriptan | Sumatriptan an | Sumatriptan ga | Sumatriptan generichealth | Sumatriptan Pfizer | Sumatriptan Rbx | Sumatriptan sandoz | Suvalan | Terry White Chemists Sumatriptan | Trust sumatriptan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Sumigran</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Doc Sumatriptan | Finigraine | Imitrex | Sumatriptan eg</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Amigren | Headan | Imigran</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Succinato de sumatriptana | Sumatriptana | Sumax | Sutriptan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptan actavis | Sumatriptan Helvepharm | Sumatriptan Mepha | Sumatriptan sandoz | Sumatriptan spirig | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Liotrex | Somatran</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dan tong jing | Imigran | You shu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Calmigran | Imigran | Imigran Fdt | Megrelan | Migragesin | Sitran | Sumatriptan | Sumigran</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo sumatriptan | Cinie | Frimig | Imigran | Rosemig | Sumamigren | Sumatriptan accord | Sumatriptan actavis | Sumatriptan aurovitas | Sumatriptan Orion | Sumatriptan Teva | Sumigra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Migrapen | Sumatriptan | Sumatriptan 1 A Pharma | Sumatriptan Aiwa | Sumatriptan al | Sumatriptan aurobindo | Sumatriptan aurus | Sumatriptan basics | Sumatriptan beta | Sumatriptan bluefish | Sumatriptan dura | Sumatriptan Hexal N | Sumatriptan Hormosan | Sumatriptan Neurax | Sumatriptan puren | Sumatriptan ratiopharm | Sumavel dosepro | Tempil</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Etimigran | Imigran | Migrafel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Triptocal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cinie | Imigran | Imigran Fdt | Sumatriptan | Sumatriptan actavis | Sumatriptan sandoz | Sumatriptan stada</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Credosan | Imigran | Megatab | Sumagraine | Sumaptan | Sumigran</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arcoiran | Imigran | Novelian | Sumamylan | Sumatriptan aurobindo | Sumatriptan aurovitas | Sumatriptan bluefish | Sumatriptan mylan | Sumatriptan sandoz | Sumatriptan sun | Sumatriptan UR</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cinie | Imigran | Imigran radis | Oriptan | Sumaratio | Sumatriptan accord | Sumatriptan actavis | Sumatriptan bluefish | Sumatriptan bmm pharma | Sumatriptan eql pharma | Sumatriptan ratiopharm | Sumatriptan sandoz | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imigrane | Imiject | Sumatriptan arrow | Sumatriptan sun | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Imigran radis | Imigran recovery | Migraitan | Sumatriptan | Sumatriptan Kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Altaxa | Forcet | Imigran | Sumatriptan/Generics | Sumatriptan/Teva | Sutriptan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo sumatriptan | Imigran | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumigra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Illument | Imigran | Imigran Sprint | Sumatriptan Orion | Sumatriptan Polpharma | Triptagram</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cetatrex | Imitrex | Triptagic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Migrastat | Sumalieve | Sumatran | Sumatran relief | Sumatriptan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Imitrex | Sumatridex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Migratan | Somatran | Suminat | Sumitrex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptan | Sumatriptan accord | Sumatriptan actavis | Sumatriptan aurobindo | Sumatriptan Doc | Sumatriptan dr reddy's | Sumatriptan eg | Sumatriptan grp | Sumatriptan Myl | Sumatriptan Ranbaxy | Sumatriptan sandoz | Sumatriptan sun | Sumatriptan Winthrop | Triptalidon</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Migranol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptan | Sumatriptan amel | Sumatriptan aspen | Sumatriptan ffp</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumafix</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Imigran FD | Mygran | Sugran | Sumatran</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Imigran</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Imigran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cinie | Illument | Imigran | Migriptan | Sumatriptan actavis | Sumatriptan Ranbaxy | Sumatriptan stada | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Imitrex | Sumatriptan eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cinie | Illument | Imigran | Sumamigren | Sumatriptan actavis | Sumatriptan dexcel | Sumatriptan Ranbaxy</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Imigran</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fermig | Gesigran | Imigran | Nograine | Psicotron | Sumatriptan | Sumitrex | Tebegran</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo sumatriptan | Imigran | Striptan | Sumatran | Sumitran</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptan | Sumatriptan a | Sumatriptan accord | Sumatriptan actavis | Sumatriptan cf | Sumatriptan Focus | Sumatriptan Merck | Sumatriptan pch | Sumatriptan ratiopharm | Sumatriptan sandoz | Sumatriptan sun</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptan amneal | Sumatriptan aristo | Sumatriptan aurobindo | Sumatriptan bluefish | Sumatriptan bmm pharma | Sumatriptan copyfarm | Sumatriptan ratiopharm | Sumatriptan sun</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo sumatriptan | Arrow Sumatriptan | Clustran | Imigran | Mygran</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Adracon | Imigran | Sumatriptan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumigran</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Imitrex | Migrinex | Nimigran | Sumagrane | Sumatec | Sumig</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amigrenex | ApoMigra | Apomigra | Cinie | Frimig | Imigran | Sumamigren | Sumatriptan aurovitas | Sumatriptan medical valley | Sumatriptan Pfizer | Sumatriptan sun | Sumigra | Triptagram</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Imitrex | Onzetra xsail | Sumatriptan | Tosymra | Zembrace symtouch</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptano generis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Tundra</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apigrane | Imigran | Imigran Spray | Imigran Subject</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatriptan sun | Xibimer</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amigrenin | Imigran | Mygrepam | Rapimed | Sumamigren | Sumarin | Sumatriptan | Sumatriptan adipharm | Sumatriptan OBL | Sumatriptan pfizer | Sumatriptan Teva | Sumig | Sumitran</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo sumatriptan | Imigran | Oratab | Pms Sumatriptan | Sumarex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Imigran novum | Oriptan | Sumatriptan 2care4 | Sumatriptan abacus medicine | Sumatriptan abece | Sumatriptan accord | Sumatriptan actavis | Sumatriptan amneal | Sumatriptan apofri | Sumatriptan arrow | Sumatriptan aurobindo | Sumatriptan bluefish | Sumatriptan bmm pharma | Sumatriptan bristol | Sumatriptan copyfarm | Sumatriptan eql pharma | Sumatriptan glaxosmithkline | Sumatriptan mylan | Sumatriptan ratiopharm | Sumatriptan sandoz | Sumatriptan stada | Sumatriptan sun | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatran</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Imigran Sprint | Sumacta | Sumigra</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumamigren | Sumatriptan Orion | Sumatriptan Teva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Siagran</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Imigran</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Sumatran</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Imigran Fdt</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Algomax | Antimigrenum | Imigran | Migranol | Stopmigren | Sumamigren</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Balmitan | Imigran</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Imigran | Migraval</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Sumatriptan | Arrow Sumatriptan | Imigran | Migrex otc | Triptam</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Imigran</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15037686">
<a name="15037686"></a>Ahonen K, Hämäläinen ML, Rantala H, et al, "Nasal Sumatriptan Is Effective in Treatment of Migraine Attacks in Children: A Randomized Trial," <i>Neurology</i>, 2004, 62(6):883-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15037686/pubmed" id="15037686" target="_blank">15037686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17151774">
<a name="17151774"></a>Al Ali AM, Straatman LP, Allard MF, Ignaszewski AP. Eosinophilic myocarditis: case series and review of literature. <i>Can J Cardiol</i>. 2006;22(14):1233-1237. doi:10.1016/s0828-282x(06)70965-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/17151774/pubmed" id="17151774" target="_blank">17151774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27211561">
<a name="27211561"></a>Albieri V, Olsen TS, Andersen KK. Risk of stroke in migraineurs using triptans. Associations with age, sex, stroke severity and subtype. <i>EBioMedicine</i>. 2016;6:199-205. doi:10.1016/j.ebiom.2016.02.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/27211561/pubmed" id="27211561" target="_blank">27211561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet</i>
<i>Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33730376">
<a name="33730376"></a>Amundsen S, Nordeng H, Fuskevåg OM, Nordmo E, Sager G, Spigset O. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. <i>Basic Clin Pharmacol Toxicol</i>. 2021;128(6):795-804. doi:10.1111/bcpt.13579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/33730376/pubmed" id="33730376" target="_blank">33730376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16767537">
<a name="16767537"></a>Arora A, Arora S. Spontaneous splenic infarction associated with sumatriptan use. <i>J Headache Pain</i>. 2006;7(4):214-216. doi:10.1007/s10194-006-0291-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/16767537/pubmed" id="16767537" target="_blank">16767537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17868284">
<a name="17868284"></a>Barbanti P, Fabbrini G, Berardelli A. Acute pathological laughter induced by sumatriptan. <i>Cephalalgia</i>. 2008;28(1):92-93. doi:10.1111/j.1468-2982.2007.01433.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/17868284/pubmed" id="17868284" target="_blank">17868284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977405">
<a name="20977405"></a>Barra S, Lanero S, Madrid A, et al. Sumatriptan therapy for headache and acute myocardial infarction. <i>Expert Opin Pharmacother</i>. 2010;11(16):2727-2737. doi:10.1517/14656566.2010.522567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20977405/pubmed" id="20977405" target="_blank">20977405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8845562">
<a name="8845562"></a>Benson JM, Zorn SL, Book LS. Sumatriptan in the treatment of cyclic vomiting. <i>Ann Pharmacother</i>. 1995;29(10):997-999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8845562/pubmed" id="8845562" target="_blank">8845562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33852763">
<a name="33852763"></a>Bjørk MH, Kristoffersen ES, Tronvik E, Egeland Nordeng HM. Management of cluster headache and other trigeminal autonomic cephalalgias in pregnancy and breastfeeding. <i>Eur J Neurol</i>. 2021;28(7):2443-2455. doi:10.1111/ene.14864<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/33852763/pubmed" id="33852763" target="_blank">33852763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909130">
<a name="7909130"></a>Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ. Sumatriptan-induced stroke in sagittal sinus thrombosis. <i>Lancet</i>. 1994;343(8905):1105-1106. doi:10.1016/s0140-6736(94)90220-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/7909130/pubmed" id="7909130" target="_blank">7909130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19456882">
<a name="19456882"></a>Chalaupka FD. Acute myocardial infarction with sumatriptan: a case report and review of the literature. <i>Headache</i>. 2009;49(5):762-764. doi:10.1111/j.1526-4610.2009.01409.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/19456882/pubmed" id="19456882" target="_blank">19456882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8014044">
<a name="8014044"></a>Chiari M, Manzoni GC, Van de Geijn EJ. Ischemic optic neuropathy after sumatriptan in a migraine with aura patient. <i>Headache</i>. 1994;34(4):237-238. doi:10.1111/j.1526-4610.1994.hed3404237_2.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8014044/pubmed" id="8014044" target="_blank">8014044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11342701">
<a name="11342701"></a>Combremont PC, Marcus EM. Intracranial hemorrhages associated with sumatriptan. <i>Neurology</i>. 2001;56(9):1243-1244. doi:10.1212/wnl.56.9.1243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11342701/pubmed" id="11342701" target="_blank">11342701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coulter.2002">
<a name="Coulter.2002"></a>Coulter D. Cerebrovascular events with sumatriptan. Medsafe. New Zealand Medicines and Medical Devices Safety Authority. <a href="https://www.medsafe.govt.nz/profs/PUarticles/sumatriptan.htm" target="_blank">https://www.medsafe.govt.nz/profs/PUarticles/sumatriptan.htm</a>. Published March 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19804390">
<a name="19804390"></a>Cunnington M, Ephross S, and Churchill P, "The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?" <i>Headache</i>, 2009, 49(10):1414-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/19804390/pubmed" id="19804390" target="_blank">19804390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22823482">
<a name="22823482"></a>Da Silva AN and Tepper SJ, "Acute Treatment of Migraines," <i>CNS Drugs</i>, 2012, 26(10):823-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22823482/pubmed" id="22823482" target="_blank">22823482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7503094">
<a name="7503094"></a>Dachs R, Vitillo J. Angioedema associated with sumatriptan administration. <i>Am J Med</i>. 1995;99(6):684-685. doi:10.1016/s0002-9343(99)80258-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/7503094/pubmed" id="7503094" target="_blank">7503094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15596760">
<a name="15596760"></a>Dash S, Bogdanova O, Xavier A, Farkas J, Pullicino P. Cerebral vasospasm from sumatriptan. <i>Neurology</i>. 2004;63(11):2128. doi:10.1212/01.wnl.0000140621.32871.18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15596760/pubmed" id="15596760" target="_blank">15596760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22336849">
<a name="22336849"></a>Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. <i>Cochrane Database Syst Rev</i>. 2012;(2):CD008615. doi: 10.1002/14651858.CD008615.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22336849/pubmed" id="22336849" target="_blank">22336849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15147249">
<a name="15147249"></a>Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. <i>Headache</i>. 2004a;44(5):414-425. doi:10.1111/j.1526-4610.2004.04078.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15147249/pubmed" id="15147249" target="_blank">15147249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15149490">
<a name="15149490"></a>Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. <i>Headache</i>. 2004b;44(suppl 1):S20-S30. doi:10.1111/j.1526-4610.2004.04105.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15149490/pubmed" id="15149490" target="_blank">15149490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15154851">
<a name="15154851"></a>Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. <i>Cephalalgia</i>. 2004c;24(6):417-424. doi:10.1111/j.1468-2982.2004.00694.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15154851/pubmed" id="15154851" target="_blank">15154851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33792783">
<a name="33792783"></a>Dudman DC, Tauqeer F, Kaur M, Ritchey ME, Li H, Lopez-Leon S. A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project. <i>J Neurol.</i> 2022;269(2):742-749. doi:10.1007/s00415-021-10534-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/33792783/pubmed" id="33792783" target="_blank">33792783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24805878">
<a name="24805878"></a>Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. <i>Headache</i>. 2014;54(7):1158-1172. doi: 10.1111/head.12375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/24805878/pubmed" id="24805878" target="_blank">24805878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18092054">
<a name="18092054"></a>Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports. <i>MedGenMed</i>. 2007;9(3):48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/18092054/pubmed" id="18092054" target="_blank">18092054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20618823">
<a name="20618823"></a>Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. <i>Headache</i>. 2010;50(6):1089-1099. doi:10.1111/j.1526-4610.2010.01691.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20618823/pubmed" id="20618823" target="_blank">20618823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2016">
<a name="FDA.2016"></a>FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. <a href="https://www.fda.gov/media/96472/download" target="_blank">https://www.fda.gov/media/96472/download</a>. Published March 22, 2016a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2006">
<a name="FDA.2006"></a>FDA Safety Alert. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). <a href="http://wayback.archive-it.org/7993/20171115034259/https:/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085845.htm" target="_blank">http://wayback.archive-it.org/7993/20171115034259/https:/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085845.htm</a>. Published July 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12383060">
<a name="12383060"></a>Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. <i>Cephalalgia</i>. 2002;22(8):633-658. doi:10.1046/j.1468-2982.2002.00404.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/12383060/pubmed" id="12383060" target="_blank">12383060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22755550">
<a name="22755550"></a>Fine A, Bastings E. Triptans and serotonin syndrome. <i>Headache</i>. 2012;52(7):1184-1188. doi:10.1111/j.1526-4610.2012.02184.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22755550/pubmed" id="22755550" target="_blank">22755550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30315014">
<a name="30315014"></a>Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or <i>serotonin toxicity</i>). <i>Can Fam Physician</i>. 2018;64(10):720-727.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/30315014/pubmed" id="30315014" target="_blank">30315014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1653135">
<a name="1653135"></a>Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. <i>Eur Neurol</i>. 1991;31(5):291-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/1653135/pubmed" id="1653135" target="_blank">1653135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10940090">
<a name="10940090"></a>Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. <i>Headache</i>. 2000;40(7):521-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/10940090/pubmed" id="10940090" target="_blank">10940090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24163282">
<a name="24163282"></a>Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. <i>Cephalalgia</i>. 2014;34(5):365-375. doi:10.1177/0333102413510213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/24163282/pubmed" id="24163282" target="_blank">24163282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190330">
<a name="12190330"></a>Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Clinical pharmacokinetics of intranasal sumatriptan. <i>Clin Pharmacokinet</i>. 2002;41(11):801-811. doi:10.2165/00003088-200241110-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/12190330/pubmed" id="12190330" target="_blank">12190330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7841582">
<a name="7841582"></a>Garcia G, Kaufman MB, Colucci RD. Dystonic reaction associated with sumatriptan. <i>Ann Pharmacother</i>. 1994;28(10):1199. doi:10.1177/106002809402801015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/7841582/pubmed" id="7841582" target="_blank">7841582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9475817">
<a name="9475817"></a>Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. <i>Ann Pharmacother</i>. 1998;32(1):33-38. doi:10.1345/aph.17204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/9475817/pubmed" id="9475817" target="_blank">9475817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21681368">
<a name="21681368"></a>Gazioglu S, Boz C, Ozmenoglu M. Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan. <i>Neurol Sci</i>. 2012;33(1):125-128. doi:10.1007/s10072-011-0651-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/21681368/pubmed" id="21681368" target="_blank">21681368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19925619">
<a name="19925619"></a>Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. <i>Headache</i>. 2010;50(2):264-272. doi:10.1111/j.1526-4610.2009.01575.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/19925619/pubmed" id="19925619" target="_blank">19925619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17381558">
<a name="17381558"></a>Goadsby PJ, Dodick DW, Almas M, et al. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. <i>Cephalalgia</i>. 2007;27(3):254-262. doi:10.1111/j.1468-2982.2007.01278.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/17381558/pubmed" id="17381558" target="_blank">17381558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16109122">
<a name="16109122"></a>Gregor N, Schlesiger C, Akova-Oztürk E, Kraemer C, Husstedt IW, Evers S. Treatment of cluster headache attacks with less than 6 mg subcutaneous sumatriptan. <i>Headache</i>. 2005;45(8):1069-1072.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/16109122/pubmed" id="16109122" target="_blank">16109122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18174091">
<a name="18174091"></a>Gunner KB, Smith HD, and Ferguson LE, "Practice Guideline for Diagnosis and Management of Migraine Headaches in Children and Adolescents: Part Two," <i>J Pediatr Health Care</i>, 2008, 22(1):52-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/18174091/pubmed" id="18174091" target="_blank">18174091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14981171">
<a name="14981171"></a>Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. <i>Neurology</i>. 2004;62(4):563-568. doi:10.1212/01.wnl.0000110312.36809.7f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/14981171/pubmed" id="14981171" target="_blank">14981171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9109909">
<a name="9109909"></a>Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? <i>Neurology</i>. 1997;48(4):1100-1103. doi:10.1212/wnl.48.4.1100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/9109909/pubmed" id="9109909" target="_blank">9109909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11554957">
<a name="11554957"></a>Hershey AD, Powers SW, LeCates S, et al, “Effectiveness of Nasal Sumatriptan in 5- to 12-Year-Old Children,” <i>Headache</i>, 2001, 41(7):693-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11554957/pubmed" id="11554957" target="_blank">11554957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21147834">
<a name="21147834"></a>Hikita T, Kodama H, Kaneko S, et al. Sumatriptan as a treatment for cyclic vomiting syndrome: a clinical trial. <i>Cephalalgia</i>. 2011;31(4):504-507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/21147834/pubmed" id="21147834" target="_blank">21147834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24909575">
<a name="24909575"></a>Hill SE, Kirsten L. Triptan-induced torsades de pointes and ventricular fibrillation cardiac arrest: case report and review of the literature. <i>Curr Drug Saf</i>. 2014;9(3):236-239. doi:10.2174/1574886309666140601210750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/24909575/pubmed" id="24909575" target="_blank">24909575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20051552">
<a name="20051552"></a>Hodge JA, Hodge KD. Ischemic colitis related to sumatriptan overuse. <i>J Am Board Fam Med</i>. 2010;23(1):124-127. doi:10.3122/jabfm.2010.01.090086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20051552/pubmed" id="20051552" target="_blank">20051552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28562545">
<a name="28562545"></a>Hsu CR, Chen YH, Tai MC, Lu DW. Sumatriptan-induced angle-closure glaucoma: A case report. <i>Medicine (Baltimore)</i>. 2017;96(22):e6953. doi:10.1097/MD.0000000000006953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/28562545/pubmed" id="28562545" target="_blank">28562545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imitrex.1">
<a name="Imitrex.1"></a>Imitrex Statdose System (sumatriptan) [prescribing information]. Durham, NC: GlaxoSmithKline; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imitrex.2">
<a name="Imitrex.2"></a>Imitrex nasal spray (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imitrex.3">
<a name="Imitrex.3"></a>Imitrex tablets (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imitrex.4">
<a name="Imitrex.4"></a>Imitrex tablets (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imitrex.5">
<a name="Imitrex.5"></a>Imitrex (sumatriptan) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7560482">
<a name="7560482"></a>Jayamaha JE, Street MK. Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. <i>Intensive Care Med</i>. 1995;21(1):82-83. doi:10.1007/BF02425161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/7560482/pubmed" id="7560482" target="_blank">7560482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26587110">
<a name="26587110"></a>Jensen C, Riddle M. ST-elevation myocardial infarction after sumatriptan ingestion in patient with normal coronary arteries. <i>West J Emerg Med</i>. 2015;16(5):781-783. doi:10.5811/westjem.2015.6.25920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/26587110/pubmed" id="26587110" target="_blank">26587110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19794103">
<a name="19794103"></a>Kakisaka Y, Wakusawa K, Sato I, et al. Successful treatment with sumatriptan in a case with cyclic vomiting syndrome combined with 18q- syndrome. <i>J Child Neurol</i>. 2009;24(12):1561-1563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/19794103/pubmed" id="19794103" target="_blank">19794103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21751829">
<a name="21751829"></a>Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. <i>Drug Saf</i>. 2011;34(8):691-703. doi:10.2165/11590370-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/21751829/pubmed" id="21751829" target="_blank">21751829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27904122">
<a name="27904122"></a>Kato Y, Hayashi T, Mizuno S, et al. Triptan-induced reversible cerebral vasoconstriction syndrome: two case reports with a literature review. <i>Intern Med</i>. 2016;55(23):3525-3528. doi:10.2169/internalmedicine.55.7185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/27904122/pubmed" id="27904122" target="_blank">27904122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26949933">
<a name="26949933"></a>Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers. <i>Br J Clin Pharmacol</i>. 2016;82(1):6-16. doi:10.1111/bcp.12912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/26949933/pubmed" id="26949933" target="_blank">26949933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9759693">
<a name="9759693"></a>Knudsen JF, Friedman B, Chen M, Goldwasser JE. Ischemic colitis and sumatriptan use. <i>Arch Intern Med</i>. 1998;158(17):1946-1948. doi:10.1001/archinte.158.17.1946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/9759693/pubmed" id="9759693" target="_blank">9759693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159612">
<a name="30159612"></a>Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: what is new in 2018? <i>Curr Gastroenterol Rep</i>. 2018;20(10):46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/30159612/pubmed" id="30159612" target="_blank">30159612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20036167">
<a name="20036167"></a>Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. <i>Seizure</i>. 2010;19(2):69-73. doi:10.1016/j.seizure.2009.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20036167/pubmed" id="20036167" target="_blank">20036167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11279937">
<a name="11279937"></a>Laine K, Raasakka T, Mäntynen J, Saukko P. Fatal cardiac arrhythmia after oral sumatriptan. <i>Headache</i>. 1999;39(7):511-512. doi:10.1046/j.1526-4610.1999.3907511.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11279937/pubmed" id="11279937" target="_blank">11279937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lee.2020">
<a name="Lee.2020"></a>Lee AY, Pucar PA, Smoth AJ. Sumatriptan anaphylaxis: A headache of an allergy. <i>Neurol Clin Pract</i>. May 2020. doi:10.1212/CPJ.0000000000000848</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27283278">
<a name="27283278"></a>Lee MJ, Lee C, Chung CS. The migraine-stroke connection. <i>J Stroke</i>. 2016;18(2):146-156. doi:10.5853/jos.2015.01683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/27283278/pubmed" id="27283278" target="_blank">27283278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31566723">
<a name="31566723"></a>Leroux E, Rothrock J. Triptans for migraine patients with vascular risks: new insights, new options. <i>Headache</i>. 2019;59(9):1589-1596. doi:10.1111/head.13656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/31566723/pubmed" id="31566723" target="_blank">31566723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Li.2022">
<a name="Li.2022"></a>Li B UK. Cyclic vomiting syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728540">
<a name="18728540"></a>Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. <i>J Pediatr Gastroenterol Nutr</i>. 2008;47(3):379-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/18728540/pubmed" id="18728540" target="_blank">18728540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10228291">
<a name="10228291"></a>Li BU, Murray RD, Heitlinger LA, Robbins JL, Hayes JR. Is cyclic vomiting syndrome related to migraine? <i>J Pediatr</i>. 1999;134(5):567-572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/10228291/pubmed" id="10228291" target="_blank">10228291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8783473">
<a name="8783473"></a>Linder SL, "Subcutaneous Sumatriptan in the Clinical Setting: The First 50 Consecutive Patients With Acute Migraine in a Pediatric Neurology Office Practice," <i>Headache</i>, 1996, 36(7):419-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8783473/pubmed" id="8783473" target="_blank">8783473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120496">
<a name="9120496"></a>López-Alemany M, Ferrer-Tuset C, Bernácer-Alpera B. Akathisia and acute dystonia induced by sumatriptan. <i>J Neurol</i>. 1997;244(2):131-132. doi:10.1007/s004150050062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/9120496/pubmed" id="9120496" target="_blank">9120496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15149489">
<a name="15149489"></a>Maassen Van Den Brink A, Saxena PR. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. <i>Headache</i>. 2004;44(suppl 1):S13-S19. doi:10.1111/j.1526-4610.2004.04104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15149489/pubmed" id="15149489" target="_blank">15149489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7843952">
<a name="7843952"></a>MacDonald JT. Treatment of juvenile migraine with subcutaneous sumatriptan. <i>Headache</i>. 1994;34(10):581-582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/7843952/pubmed" id="7843952" target="_blank">7843952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29593023">
<a name="29593023"></a>Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. <i>BMJ Open</i>. 2018;8(3):e020498. doi:10.1136/bmjopen-2017-020498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/29593023/pubmed" id="29593023" target="_blank">29593023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-May.2019">
<a name="May.2019"></a>May A. Cluster headache: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31620447">
<a name="31620447"></a>Mohan J, Parekh A, DeYoung M. Sumatriptan induced takotsubo cardiomyopathy; the headache of the heart: a case report. <i>Front Cardiovasc Med</i>. 2019;6:134. doi:10.3389/fcvm.2019.00134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/31620447/pubmed" id="31620447" target="_blank">31620447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8682677">
<a name="8682677"></a>Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. <i>Headache</i>. 1996;36(5):329-331. doi:10.1046/j.1526-4610.1996.3605329.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8682677/pubmed" id="8682677" target="_blank">8682677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22946832">
<a name="22946832"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng HM, "Errata in 'Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study,'" <i>Headache</i>, 2012, 52(8):1319-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22946832/pubmed" id="22946832" target="_blank">22946832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20132339">
<a name="20132339"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng H, "Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study," <i>Headache</i>, 2010, 50(4):563-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20132339/pubmed" id="20132339" target="_blank">20132339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23884894">
<a name="23884894"></a>Nezvalová-Henriksen K, Spigset O, Nordeng H, et al. Triptan safety during pregnancy: a Norwegian population registry study. <i>Eur J Epidemiol</i>. 2013;28(9):759-769. doi:10.1007/s10654-013-9831-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/23884894/pubmed" id="23884894" target="_blank">23884894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24442762">
<a name="24442762"></a>Nguyen TQ, Lewis JH. Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS. <i>Drug Saf</i>. 2014;37(2):109-121. doi:10.1007/s40264-013-0134-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/24442762/pubmed" id="24442762" target="_blank">24442762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27858938">
<a name="27858938"></a>Novitskaya ES, Cates CA, Bowes OM, Vivian AJ. Triptans and third nerve paresis: a case series of three patients. <i>Eye (Lond)</i>. 2017;31(3):503-505. doi:10.1038/eye.2016.256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/27858938/pubmed" id="27858938" target="_blank">27858938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Onzetra.1">
<a name="Onzetra.1"></a>Onzetra Xsail (sumatriptan nasal powder) [prescribing information]. Morristown, NJ: Currax Pharmaceuticals LLC; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9731945">
<a name="9731945"></a>Oterino A, Pascual J. Sumatriptan-induced axial dystonia in a patient with cluster headache. <i>Cephalalgia</i>. 1998;18(6):360-361. doi:10.1046/j.1468-2982.1998.1806358-4.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/9731945/pubmed" id="9731945" target="_blank">9731945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31413171">
<a name="31413171"></a>Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. <i>Neurology</i>. 2019;93(11):487-499. doi:10.1212/WNL.0000000000008095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/31413171/pubmed" id="31413171" target="_blank">31413171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15663606">
<a name="15663606"></a>Pascual J, Muñoz P. Correlation between lipophilicity and triptan outcomes. <i>Headache</i>. 2005;45(1):3-6. doi:10.1111/j.1526-4610.2005.05003.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15663606/pubmed" id="15663606" target="_blank">15663606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16472339">
<a name="16472339"></a>Pfadenhauer K, Schönsteiner T, Keller H. The risks of sumatriptan administration in patients with unrecognized subarachnoid haemorrhage (SAH). <i>Cephalalgia</i>. 2006;26(3):320-323. doi:10.1111/j.1468-2982.2006.00979.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/16472339/pubmed" id="16472339" target="_blank">16472339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8792043">
<a name="8792043"></a>Pradalier A, Katchourine I, Vincent D. Delayed urticaria with sumatriptan. <i>Cephalalgia</i>. 1996;16(4):280-281. doi:10.1046/j.1468-2982.1996.1604280-3.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8792043/pubmed" id="8792043" target="_blank">8792043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10524661">
<a name="10524661"></a>Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. <i>Cephalalgia</i>. 1999;19(7):668-675. doi:10.1046/j.1468-2982.1999.019007668.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/10524661/pubmed" id="10524661" target="_blank">10524661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30169369">
<a name="30169369"></a>Ramineni KK, Jakkani RK, Girgani S, Balani A, Satyanarayan S. Triptan-induced reversible cerebral vasoconstriction syndrome presenting with thunderclap headache and paraparesis. <i>Neurologist</i>. 2018;23(5):160-162. doi:10.1097/NRL.0000000000000193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/30169369/pubmed" id="30169369" target="_blank">30169369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432623">
<a name="27432623"></a>Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: the American Headache Society evidence-based guidelines. <i>Headache</i>. 2016;56(7):1093-1106. doi:10.1111/head.12866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/27432623/pubmed" id="27432623" target="_blank">27432623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23921799">
<a name="23921799"></a>Roberto G, Piccinni C, D'Alessandro R, Poluzzi E. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. <i>Cephalalgia</i>. 2014;34(1):5-13. doi:10.1177/0333102413499649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/23921799/pubmed" id="23921799" target="_blank">23921799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11192144">
<a name="11192144"></a>Rothner AD, Winner P, Nett R, et al, "One-Year Tolerability and Efficacy of Sumatriptan Nasal Spray in Adolescents With Migraine: Results of a Multicenter, Open-Label Study," <i>Clin Ther</i>, 2000, 22(12):1533-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11192144/pubmed" id="11192144" target="_blank">11192144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saadati.2001">
<a name="Saadati.2001"></a>Saadati HG, Chane M, Sadun AA. Ocular motility problems associated with sumatriptan administration. <i>Ann Ophthalmol.</i> 2001;33:231–232. doi:10.1007/s12009-001-0033-x</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24085027">
<a name="24085027"></a>Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and hemorrhagic stroke: a meta-analysis. <i>Stroke</i>. 2013;44(11):3032-3038. doi:10.1161/STROKEAHA.113.002465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/24085027/pubmed" id="24085027" target="_blank">24085027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8539258">
<a name="8539258"></a>Schenker S, Yang Y, Perez A, Henderson GI, Lee MP. Sumatriptan (Imitrex) transport by the human placenta. <i>Proc Soc Exp Biol Med</i>. 1995;210(3):213-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8539258/pubmed" id="8539258" target="_blank">8539258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35296510">
<a name="35296510"></a>Schindler EAD, Burish MJ. Recent advances in the diagnosis and management of cluster headache. <i>BMJ</i>. 2022;376:e059577. doi:10.1136/bmj-2020-059577<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/35296510/pubmed" id="35296510" target="_blank">35296510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.2021">
<a name="Schwedt.2021"></a>Schwedt TJ. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22289074">
<a name="22289074"></a>Sclar DA, Robison LM, Castillo LV, et al. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. <i>Headache</i>. 2012;52(2):198-203. doi:10.1111/j.1526-4610.2011.02067.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22289074/pubmed" id="22289074" target="_blank">22289074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7851052">
<a name="7851052"></a>Scott AK. Sumatriptan clinical pharmacokinetics. <i>Clin Pharmacokinet</i>. 1994;27(5):337-344. doi: 10.2165/00003088-199427050-00002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/7851052/pubmed" id="7851052" target="_blank">7851052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17854415">
<a name="17854415"></a>Silver S, Gano D, and Gerretsen P, "Acute Treatment of Paediatric Migraine: A Meta-analysis of Efficacy," <i>J Paediatr Child Health</i>, 2008, 44(1-2):3-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/17854415/pubmed" id="17854415" target="_blank">17854415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11781419">
<a name="11781419"></a>Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G, Koroshetz WJ. Cerebral vasoconstriction and stroke after use of serotonergic drugs. <i>Neurology</i>. 2002;58(1):130-133. doi:10.1212/wnl.58.1.130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11781419/pubmed" id="11781419" target="_blank">11781419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18480219">
<a name="18480219"></a>Soldin OP, Tonning JM; Obstetric-Fetal Pharmacology Research Unit Network. Serotonin syndrome associated with triptan monotherapy. <i>N Engl J Med</i>. 2008;358(20):2185-2186. doi:10.1056/NEJMc0706410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/18480219/pubmed" id="18480219" target="_blank">18480219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20493462">
<a name="20493462"></a>Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. <i>Am J Med</i>. 2010;123(7):612-624. doi:10.1016/j.amjmed.2009.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20493462/pubmed" id="20493462" target="_blank">20493462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign Against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23216317">
<a name="23216317"></a>Stillman MJ, Tepper S, Tepper DE, Cho L. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case. <i>Headache</i>. 2013;53(1):208-216. doi:10.1111/j.1526-4610.2012.02300.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/23216317/pubmed" id="23216317" target="_blank">23216317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1322217">
<a name="1322217"></a>Stricker BH. Coronary vasospasm and sumatriptan. <i>BMJ</i>. 1992;305(6845):118. doi:10.1136/bmj.305.6845.118-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/1322217/pubmed" id="1322217" target="_blank">1322217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Somerset.1">
<a name="Somerset.1"></a>Sumatriptan succinate injection [prescribing information]. Hollywood, FL: Somerset Therapeutics LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sunku.2009">
<a name="Sunku.2009"></a>Sunku B. Cyclic vomiting syndrome: a disorder of all ages. <i>J Gastroenterol Hepatol</i>. 2009;5(7):507-515.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12904112">
<a name="12904112"></a>Tepper SJ, Millson D. Safety profile of the triptans. <i>Expert Opin Drug Saf</i>. 2003;2(2):123-132. doi:10.1517/14740338.2.2.123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/12904112/pubmed" id="12904112" target="_blank">12904112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22221260">
<a name="22221260"></a>Tepper SJ. Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice. <i>Headache</i>. 2012;52(2):195-197. doi:10.1111/j.1526-4610.2011.02076.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22221260/pubmed" id="22221260" target="_blank">22221260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11284463">
<a name="11284463"></a>Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. <i>Headache</i>. 1998;38(10):748-755. doi:10.1046/j.1526-4610.1998.3810748.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11284463/pubmed" id="11284463" target="_blank">11284463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20012125">
<a name="20012125"></a>Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man? <i>J Headache Pain</i>. 2010;11(1):5-12. doi:10.1007/s10194-009-0170-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20012125/pubmed" id="20012125" target="_blank">20012125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16097850">
<a name="16097850"></a>Tietjen GE. The risk of stroke in patients with migraine and implications for migraine management. <i>CNS Drugs</i>. 2005;19(8):683-692. doi:10.2165/00023210-200519080-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/16097850/pubmed" id="16097850" target="_blank">16097850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35002554">
<a name="35002554"></a>Tillman EM, Harvath EM. Cyclic vomiting syndrome in pediatric patients: a review of therapeutics. <i>J Pediatr Pharmacol Ther</i>. 2022;27(1):12-18. doi:10.5863/1551-6776-27.1.12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/35002554/pubmed" id="35002554" target="_blank">35002554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tosymra.1">
<a name="Tosymra.1"></a>Tosymra (sumatriptan nasal spray) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10227648">
<a name="10227648"></a>Ueberall MA and Wenzel D, "Intranasal Sumatriptan for the Acute Treatment of Migraine in Children," <i>Neurology</i>, 1999, 52(7):1507-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/10227648/pubmed" id="10227648" target="_blank">10227648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12601104">
<a name="12601104"></a>van Vliet JA, Bahra A, Martin V, et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. <i>Neurology</i>. 2003;60(4):630-633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/12601104/pubmed" id="12601104" target="_blank">12601104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15209685">
<a name="15209685"></a>Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. <i>Headache</i>. 2004;44(7):642-651. doi:10.1111/j.1526-4610.2004.04122.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15209685/pubmed" id="15209685" target="_blank">15209685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31241819">
<a name="31241819"></a>Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. <i>Neurogastroenterol Motil.</i> 2019;Suppl 2:e13604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/31241819/pubmed" id="31241819" target="_blank">31241819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32886179">
<a name="32886179"></a>Viard D, Gérard A, Tahiri J, Tieulié N, Van Obberghen E, Drici MD. Triptan overuse during pregnancy: a possible cause of placental hypoperfusion. <i>Eur J</i>
<i>Clin Pharmacol</i>. 2021;77(2):269-270. doi:10.1007/s00228-020-02991-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/32886179/pubmed" id="32886179" target="_blank">32886179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8980858">
<a name="8980858"></a>Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. <i>Cephalalgia</i>. 1996;16(8):554-559. doi:10.1046/j.1468-2982.1996.1608554.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8980858/pubmed" id="8980858" target="_blank">8980858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319709">
<a name="15319709"></a>Wasson S, Jayam VK. Coronary vasospasm and myocardial infarction induced by oral sumatriptan. <i>Clin Neuropharmacol</i>. 2004;27(4):198-200. doi:10.1097/01.wnf.0000136889.78887.6f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15319709/pubmed" id="15319709" target="_blank">15319709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17976410">
<a name="17976410"></a>Weir RA, Oldroyd KG, Walters MR. Myocardial infarction after oral sumatriptan use in a woman with normal coronary arteries. <i>Am J Med</i>. 2007;120(11):e7-e8. doi:10.1016/j.amjmed.2006.03.047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/17976410/pubmed" id="17976410" target="_blank">17976410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11167896">
<a name="11167896"></a>Welch KM, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. <i>Cephalalgia</i>. 2000;20(8):687-695. doi:10.1111/j.1468-2982.2000.00116.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11167896/pubmed" id="11167896" target="_blank">11167896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22550159">
<a name="22550159"></a>Williams SH and Kehr HA, "An Update in the Treatment of Neurologic Disorders During Pregnancy-Focus on Migraines and Seizures," <i>J Pharm Pract</i>, 2012, 25(3):341-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22550159/pubmed" id="22550159" target="_blank">22550159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11061765">
<a name="11061765"></a>Winner P, Rothner AD, Saper J, et al, “A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents,” <i>Pediatrics</i>, 2000, 106(5):989-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11061765/pubmed" id="11061765" target="_blank">11061765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Winner.2006">
<a name="Winner.2006"></a>Winner P, Rothner AD, Wooten JD, et al, "Sumatriptan Nasal Spray in Adolescent Migraineurs: A Randomized, Double-Blind, Placebo-Controlled, Acute Study," <i>Headache</i>, 2006, 46(2):212-22.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8866921">
<a name="8866921"></a>Wojnar-Horton RE, Hackett LP, Yapp P, Dusci LJ, Paech M, Ilett KF. Distribution and excretion of sumatriptan in human milk. <i>Br J Clin Pharmacol</i>. 1996;41(3):217-221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8866921/pubmed" id="8866921" target="_blank">8866921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5)(suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30240072">
<a name="30240072"></a>Yusuf A, Chia V, Xue F, Mikol DD, Bollinger L, Cangialose C. Use of existing electronic health care databases to evaluate medication safety in pregnancy: triptan exposure in pregnancy as a case study. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(12):1309-1315. doi:10.1002/pds.4658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/30240072/pubmed" id="30240072" target="_blank">30240072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zembrace.1">
<a name="Zembrace.1"></a>Zembrace SymTouch (sumatriptan succinate) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; February 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12821 Version 552.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
